275 results on '"Coskun, Tamer"'
Search Results
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
4. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
5. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
6. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
7. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
8. New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
9. Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster
10. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes
11. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
12. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
14. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
15. GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice.
16. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
17. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice
18. Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D
19. LY3437943 (LY), A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2D after 12 Weeks of Treatment
20. Short-term cooling increases serum triglycerides and small high-density lipoprotein levels in humans
21. Giant cell tumor of tendon sheath in the hand: analysis of risk factors for recurrence in 50 cases
22. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
23. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
24. Evaluation of operational parameters and its relation on the stoichiometry of Fenton’s oxidation to textile wastewater
25. Review for "The effects of kisspeptin on food intake in women with overweight or obesity"
26. Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure
27. Tirzepatide reduces appetite, energy intake and fat mass in people with T2D
28. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
29. Glucose‐dependent insulinotropic polypeptide counteracts diet‐induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin‐responsive and proopiomelanocortin neurons in the arcuate nucleus
30. Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist
31. Investigation of the parameters affecting the functional results in conservatively followed distal radius fractures
32. The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat
33. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
34. The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying.
35. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
36. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
37. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
38. Fluoroscopic visualization of 4+5 extensor compartmental arteries in Kienböck's Disease.
39. Selection of distal fusion level in posterior instrumentation and fusion of Scheuermann kyphosis: is fusion to sagittal stable vertebra necessary?
40. 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
41. 714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
42. 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment
43. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
44. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
45. DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES
46. Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First in Human Dose Study in Healthy Subjects
47. Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
48. Relationship between carpal bone morphology and scaphoid fracture location.
49. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.
50. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.